Valdecoxib
Structural formula | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | |||||||||||||||||||
Non-proprietary name | Valdecoxib | ||||||||||||||||||
other names |
4- (5-methyl-3-phenyl-isoxazol-4-yl) benzenesulfonamide |
||||||||||||||||||
Molecular formula | C 16 H 14 N 2 O 3 S | ||||||||||||||||||
Brief description |
colorless to yellowish powder |
||||||||||||||||||
External identifiers / databases | |||||||||||||||||||
|
|||||||||||||||||||
Drug information | |||||||||||||||||||
ATC code | |||||||||||||||||||
Drug class | |||||||||||||||||||
properties | |||||||||||||||||||
Molar mass | 314.36 g · mol -1 | ||||||||||||||||||
solubility | |||||||||||||||||||
safety instructions | |||||||||||||||||||
|
|||||||||||||||||||
Toxicological data | |||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Valdecoxib (trade name Bextra ® ) is a drug from the group of cyclooxygenase-2 inhibitors (syn. COX-2 inhibitors or coxibs) from Pfizer .
In February 2005, the US FDA ordered Pfizer to withdraw valdecoxib from the market. The reasons were:
- Lack of long-term data on cardiovascular safety
- Severe allergic skin reactions have been reported after the use of valdecoxib
- Lack of evidence of an advantage of valdecoxib over other NSAIDs
After being suspended in 2005, European approval has now expired.
Pfizer was tried again in September 2009 for illegally marketing the analgesic . The company had agreed to pay a total of $ 2.3 billion in damages for the civil and criminal charges; this is the largest sum ever paid as a fine by a pharmaceutical company .
Individual evidence
- ↑ a b c d e f data sheet valdecoxib from Sigma-Aldrich , accessed on May 20, 2017 ( PDF ).
- ^ Sarfaraz K. Niazi: Handbook of Pharmaceutical Manufacturing Formulations. Taylor & Francis, 2004, ISBN 978-0-849-31746-0 , p. 260 ( limited preview in Google book search).
- ↑ FDA: Public Health Advisory - FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) , April 7, 2005.
- ↑ EMEA document 358234/2005 (PDF; 142 kB).
- ↑ Gardiner Harris: Pfizer Pays $ 2.3 Billion to Settle Marketing Case . In: The New York Times . September 2, 2009, ISSN 0362-4331 ( nytimes.com [accessed July 4, 2020]).